Novo Nordisk

October 1, 2026

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy Endpoints NewsThe Next Frontier for Obesity Drugs Isn’t…

MMedication

Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug

September 30, 2026

Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most…

MMedication

September 25, 2026

ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared…

MMedication

Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study

September 23, 2026

Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of…

MMedication

Hundreds of lawsuits filed against some GLP-1 Makers over vision loss

September 22, 2026

Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned…

MMedication

The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?

September 21, 2026

Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule…

HHealthcare

September 11, 2026

The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments…

MMedication

Sun Pharma Requires High Court Approval for Semaglutide Tablet Launch Amid Patent Dispute, ETPharma

August 12, 2026

New Delhi: The Delhi High Court on Tuesday asked Sun Pharma Laboratories to take its prior approval before…

MMedication

August 8, 2026

This article first appeared on GuruFocus. Amazon.com Inc. (AMZN, Financials), the e-commerce and cloud-computing company, is expanding its…

MMedication

August 2, 2026

A recent high-profile court judgment halting a Pretoria pharmacy from selling GLP-1 drugs at scale has seemingly done…

MMedication

July 24, 2026

Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in…

MMedication

Does EU Approval of Wegovy Pill Change NVO's Competitive Story?

July 20, 2026

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of…

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy – Endpoints News

Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drug

Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis

Novo’s CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study

Hundreds of lawsuits filed against some GLP-1 Makers over vision loss

The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Sun Pharma Requires High Court Approval for Semaglutide Tablet Launch Amid Patent Dispute, ETPharma

Amazon Is Bringing the Weight-Loss Drug Race to Medicare

Hairdressers selling ‘Ozempic’: SA’s wild weight loss market

Lilly to file for next-gen obesity drug approval in early 2027

Does EU Approval of Wegovy Pill Change NVO’s Competitive Story?